Literature DB >> 19768292

Effects of therapeutic angiogenesis with plasmid VEGF165 on ventricular function in a canine model of chronic myocardial infarction.

Ana Paula Furlani1, Renato A K Kalil, Iran Castro, Andrés Cañedo-Delgado, Marinez Barra, Paulo Roberto Prates, Roberto T Sant'Anna, Ivo A Nesralla.   

Abstract

OBJECTIVE: Therapeutic angiogenesis is currently under investigation in ischemic heart disease. We examined the effect on left ventricular function induced by therapeutic angiogenesis by intramyocardial injection of plasmid VEGF(165), in a canine model of chronic myocardial infarction.
METHODS: Left thoracotomy was performed in 10 mongrel dogs, and myocardial infarction induced by ligation of the major diagonal coronary artery. At 7 postoperative (p.o.) day (pre-treatment), left ventricular ejection fraction was assessed by echocardiogram, and a second procedure was done: saline or plasmid VEGF(165) at 200 mg/mL was injected over 10 points of the ischemic areas of control or treated groups, respectively. Fourteen days later (post-treatment, day 21) a control echocardiogram was performed, the animals were sacrificed and histological examination was performed.
RESULTS: Ejection fraction was maintained in the treated group: 52.45 +/- 15.1% on day 7 and 48.53 +/-11.74% on day 21 (P=0.59), and tended to decrease in the control group, from 59.3 +/- 4% to 39.37 +/- 19.43% (P=0.04), although absolute values did not differ significantly between groups. Histological examination revealed a non significant increase in capillary vessels number in all areas in treated group. Paradoxically, arterioles were significantly less in number in all areas of treated dogs.
CONCLUSION: Intramyocardial injection of plasmid VEGF(165), in this canine model of chronic myocardial infarction, resulted in preservation of left ventricular ejection fraction, contrary to the control group where left ventricular ejection fraction showed continuous decline during the experiment. Histological examination, however, was unable to explain completely these results.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19768292     DOI: 10.1590/s0102-76382009000200009

Source DB:  PubMed          Journal:  Rev Bras Cir Cardiovasc


  5 in total

Review 1.  Angiogenic growth factors in myocardial infarction: a critical appraisal.

Authors:  Hemalatha Thiagarajan; UmaMaheswari Thiyagamoorthy; Iswariya Shanmugham; Gunadharini Dharmalingam Nandagopal; Anbukkarasi Kaliyaperumal
Journal:  Heart Fail Rev       Date:  2017-11       Impact factor: 4.214

Review 2.  Gene therapy for refractory angina and cell therapy for heart failure: experience of a Brazilian research group.

Authors:  Roberto Tofani Sant'Anna; Bruna Eibel; Melissa Medeiros Markoski; Clarissa Garcia Rodrigues; Felipe Borsu de Salles; Imarilde Inês Giusti; Ivo Abrahão Nesralla; Nance Beyer Nardi; Renato Abdala Karam Kalil
Journal:  Gene Ther       Date:  2019-07-05       Impact factor: 5.250

Review 3.  Cardiovascular gene therapy for myocardial infarction.

Authors:  Maria C Scimia; Anna M Gumpert; Walter J Koch
Journal:  Expert Opin Biol Ther       Date:  2013-12-16       Impact factor: 4.388

4.  Cells involved in extracellular matrix remodeling after acute myocardial infarction.

Authors:  Larissa Ferraz Garcia; Fábio D'Aguiar Mataveli; Ana Maria Amaral Antônio Mader; Thérèse Rachell Theodoro; Giselle Zenker Justo; Maria Aparecida da Silva Pinhal
Journal:  Einstein (Sao Paulo)       Date:  2015 Jan-Mar

5.  Effects of Endothelial and Mesenchymal Stem Cells on Improving Myocardial Function in a Sheep Animal Model.

Authors:  Shahram Rabbani; Masoud Soleimani; Mohammad Sahebjam; Mohammad Imani; Seyed Mahdi Nassiri; Amir Atashi; Morteza Daliri Joupari; Ali Ghiaseddin; Mostafa Latifpour; Seyed Hossein Ahmadi Tafti
Journal:  J Tehran Heart Cent       Date:  2017-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.